Islet amyloid polypeptide amide causes peripheral insulin resistance in vivo in dogs

112Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Islet amyloid polypeptide is a 37 amino acid hormone-like peptide which is the major protein component of islet amyloid deposits commonly found in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Recent studies indicate that a physiologically active form of this peptide appears to be carboxyamidated and secreted from the insulin-producing beta cell. In order to clarify the possible in vivo actions of islet amyloid polypeptide, we have studied the effects of synthesized islet amyloid polypeptide-amide on peripheral glucose utilization by performing hyperinsulinaemic euglycaemic glucose clamp studies on dogs. Exogenously administered islet amyloid polypeptide-amide (an infusion from 1.0 to 100 μg·kg-1·h-1, over 2 h) inhibited the insulin-stimulated glucose disposal rate in a dose dependent manner. Twenty-five μg·kg-1·h-1 of islet amyloid polypeptide-amide infused via a peripheral vein significantly lowered the glucose disposal rate by 20% (from 17.4±1.7 to 14.4±1.7 mg·kg-1·min-1, n = 5, p<0.01). These findings suggest that islet amyloid polypeptide-amide causes peripheral insulin resistance in vivo. © 1990 Springer-Verlag.

Cite

CITATION STYLE

APA

Sowa, R., Sanke, T., Hirayama, J., Tabata, H., Furuta, H., Nishimura, S., & Nanjo, K. (1990). Islet amyloid polypeptide amide causes peripheral insulin resistance in vivo in dogs. Diabetologia, 33(2), 118–120. https://doi.org/10.1007/BF00401051

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free